GenArraytion Inc. has created the first test capable of identifying the Zika virus and other mosquito-caused illnesses.
The new test, called Aedes Aegypti MultiFLEX Bioassay and funded by GenArraytion, will also work with yellow, dengue and chikungunya fevers.
“The Zika virus has the potential to become a serious epidemic, with as many four million people risking exposure in the next year if the mosquito population isn’t controlled, according to the Pan American Health Organization,” Dr. R. Paul Schaudies, CEO of GenArraytion, said. “GenArraytion’s test directly identifies the virus, thereby making it easier for public health officials to rapidly pinpoint sources of infection and to eradicate infected mosquito populations.”
The test will include four regions of the Zika virus' genetic code, so that any mutation will hopefully be detected. The test did not take long to develop and will allow health care workers to test multiple mosquito-borne illnesses -- up to 20 genetic markers.
“Maryland’s innovation economy has a strong history of responding to major public health issues, and it is a great source of pride for our region that one of our members, GenArraytion, has rapidly developed a critical test in finding a solution to the Zika virus,” Phil Schiff, CEO of the Tech Council of Maryland, said.